insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.

0/5 보강
Annals of surgical oncology 2025 Vol.32(8) p. 5434-5435
Retraction 확인
출처
PubMed DOI

Omiya K, Oba A, Sugiura K, Maekawa A, Mie T, Kobayashi K, Ono Y, Ito H, Inoue Y, Takahashi Y

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Omiya K, Oba A, et al. (2025). ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.. Annals of surgical oncology, 32(8), 5434-5435. https://doi.org/10.1245/s10434-025-17458-8
MLA Omiya K, et al.. "ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.." Annals of surgical oncology, vol. 32, no. 8, 2025, pp. 5434-5435.
PMID 40397341
DOI 10.1245/s10434-025-17458-8

같은 제1저자의 인용 많은 논문 (2)